Free Trial
NYSE:PRME

Prime Medicine 5/10/2024 Earnings Report

Prime Medicine logo
$1.27 -0.02 (-1.16%)
As of 01:27 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Prime Medicine EPS Results

Actual EPS
-$0.44
Consensus EPS
-$0.45
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Prime Medicine Revenue Results

Actual Revenue
$0.59 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Prime Medicine Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Prime Medicine Earnings Headlines

FY2025 EPS Estimates for Prime Medicine Increased by Analyst
Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. Now… as new tariffs take effect, gold is breaking records again. You've hopefully already seen this in action… but gold is surpassing $3,000 per ounce for the first time EVER.
Prime Medicine FY2029 EPS Forecast Lowered by HC Wainwright
What is Wedbush's Estimate for Prime Medicine Q3 Earnings?
See More Prime Medicine Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Prime Medicine? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Prime Medicine and other key companies, straight to your email.

About Prime Medicine

Prime Medicine (NYSE:PRME), a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.

View Prime Medicine Profile

More Earnings Resources from MarketBeat